EGElnaz Gholipour-Khalili

Elnaz Gholipour-Khalili

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elnaz Gholipour-Khalili has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sensitivity and specificity of the CANTAB Paired Associates Learning test for identifying mild cognitive impairment

    by Yashar Nabizadeh, Malihe Talebi, Elnaz Gholipour-Khalili, Hamidreza Ashayeri, Mahnaz Talebi, Amirreza Naseri


  • Open Access

    Air Pollution and Parkinson’s Disease Pathology: Clinical Evidence and the Molecular Mechanisms Linking Airborne Toxicants to Neuroinflammation and Neurodegeneration

    by Sina Pakkhesal, Seyedyashar Pourebrahimian Leilabadi, Sina Hamzehzadeh, Farshad Zare, Elnaz Gholipour-Khalili, Fatemeh Malekinejad, Shahrzad Fakhkhari, Mahnaz Talebi, Amirreza Naseri

    Parkinson’s disease (PD) is a neurodegenerative condition, and its rising prevalence necessitates the urgent need to identify modifiable risk factors. Air pollution, a pervasive and also escalating public health problem, has emerged as a potential contributor to the incidence and progression of PD. As urbanization and industrialization continue to exacerbate global air pollution levels, understanding the relationship between airborne toxicants and PD is a pressing scientific and public health priority. In this review, we critically discuss the current epidemiological evidence and the cellular and molecular mechanisms underlying air pollution‐induced neurodegeneration in PD. Clinical studies associate long‐term interaction with pollutants such as nitrogen oxides, particulate matter, and ozone with increased PD risk. Evidence also suggests that air pollution worsens PD prognosis. Mechanistically, air pollution is hypothesized to contribute to PD pathogenesis through gut microbiome alternations, oxidative stress, and neuroinflammatory pathways, as well as promoting α‐synuclein aggregation.

  • Mediterranean-like diets in multiple sclerosis: A systematic review

    by H. Abbasi, F. Shakouri, R. Mosaddeghi-Heris, E. Gholipour-Khalili, F. Jahanshahlou, S. Sanaie, A. Naseri, M. Talebi


  • Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review

    by Soroush Morsali, Zahra Sabahi, Javad Kakaei, Zahra Hakimzadeh, Sana Hamidi, Elnaz Gholipour-Khalili, Sarvin Sanaie, Mahnaz Talebi, Amirreza Naseri

    Background Melatonin is a neurohormone secreted predominantly by the pineal gland that is demonstrated to be associated with the pathogenesis of multiple sclerosis (MS). This research desires to evaluate the tolerability and beneficial effects of exogenous melatonin supplementations in patients with MS. Methods This study was executed following the PRISMA 2020 statement. Both observational and interventional studies which reported the clinical effectiveness and/or safety of melatonin supplementation in patients with MS were included in this systematic review. Ovid, PubMed, Scopus, Embase, and Web of Science databases were searched and the risk of bias in included studies was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools based on study design. Results Out of 1304 results of database searches, finally, 14 articles, including 7 randomized controlled trials (RCTs), 6 case–control studies, and one quasi-experimental study, were included based on the full-text review. Included phenotypes of MS were mostly relapsing-remitting MS (RRMS) (in 11 studies); it was secondary progressive MS (SPMS) in only one study, and two other studies had a mixture of the different phenotypes. The course of treatment with melatonin supplementation was between 2 weeks and 12 months. There were no substantial safety issues. Although melatonin was associated with enhanced oxidative stress and inflammation status, concerning the clinical benefits, limited studies suggested improvements in sleep conditions, cognitive outcomes, and fatigue in MS. Discussion There are insufficient data to support the regular melatonin prescription in MS. Limitations such as the small number of included studies, the diversity of the dosage, route, and duration of melatonin administration, and the diversity of assessment tests lead to unconvincing findings in this study. There is a need for future studies to achieve a comprehensive judgment on this subject.


  • Metformin: new applications for an old drug

    by Amirreza Naseri, Sarvin Sanaie, Sina Hamzehzadeh, Sepideh Seyedi-Sahebari, Mohammad-Salar Hosseini, Elnaz Gholipour-Khalili, Reza Majidazar, Parya Seraji, Sara Daneshvar, Erfan Rezazadeh-Gavgani

    Metformin is a biguanide, evolved as one of the most widely used medicines. The applications of this component include but are not limited to reducing blood glucose, weight loss, and polycystic ovary syndrome. Studies about other probable indications have emerged, indicating that this agent can also be utilized for other purposes. In this review, applications of metformin are noticed based on the current evidence. Metformin commonly is used as an off-label drug in non-alcoholic fatty liver disease (NAFLD), but it worsens inflammation and should not be used for this purpose, according to the latest research. Metformin decreased the risk of death in patients with liver cirrhosis. It is an effective agent in the prevention and improvement of survival in patients suffering hepatocellular carcinoma. There is evidence of the beneficial effects of metformin in colorectal cancer, early-stage prostate cancer, breast cancer, urothelial cancer, blood cancer, melanoma, and bone cancer, suggesting metformin as a potent anti-tumor agent. Metformin shows neuroprotective effects and provides a potential therapeutic benefit for mild cognitive impairment and Alzheimer’s disease (AD). It also has been shown to improve mental function and reduce the incidence of dementia. Another condition that metformin has been shown to slow the progression of is Duchenne muscular dystrophy. Regarding infectious diseases, tuberculosis (TB) and coronavirus disease (COVID-19) are among the conditions suggested to be affected by metformin. The beneficial effects of metformin in cardiovascular diseases were also reported in the literature. Concerning renal function, studies showed that daily oral administration of metformin could ameliorate kidney fibrosis and normalize kidney structure and function. This study reviewed the clinical and preclinical evidence about the possible benefits of metformin based on recent studies. Numerous questions like whether these probable indications of metformin can be observed in non-diabetics, need to be described by future basic experiments and clinical studies.


  • The association of apolipoprotein E (ApoE) genotype and cognitive outcomes in multiple sclerosis; a systematic review and meta-analysis

    by Amirreza Naseri, Kosar Baghernezhad, Sepideh Seyedi-Sahebari, Seyed Ardalan Alhoseini, Elnaz Gholipour-Khalili, Fatemeh Zafarani, Mahnaz Talebi